bims-rebome Biomed News
on Management of bone metastases
Issue of 2026–02–08
five papers selected by
Alberto Selvanetti, Azienda Ospedaliera San Giovanni Addolorata



  1. Lancet Oncol. 2026 Feb;pii: S1470-2045(25)00602-3. [Epub ahead of print]27(2): e111-e122
      Malignant spinal cord compression (MSCC) is a serious complication of spinal metastases and primary spinal tumours that can severely affect quality of life and overall survival. Clinical trials have used inconsistent definitions, criteria, and endpoints, limiting comparability. We conducted a Delphi consensus process following a systematic review of prospective MSCC trials from Jan 1, 2003, to Feb 26, 2024. From June 25, 2024, to Jan 11, 2025, experts from 20 countries participated in two survey rounds, 74 in round 1 and 71 in round 2. Consensus was defined as over 75% agreement. 49 statements reached consensus, including definitions for clinical, radiological, and impending MSCC using the Bilsky scale. Experts agreed on baseline and follow-up assessments, including pain, motor and sensory function, ambulation, and urinary and anal sphincter function. Standardised functional scales, response criteria, endpoint definitions, and timing of assessments were established. A core set of mandatory and secondary endpoints was defined for different MSCC scenarios, along with minimum reporting standards for surgery and radiotherapy toxicity. These recommendations aim to standardise future MSCC trials and audits to improve data consistency and comparability.
    DOI:  https://doi.org/10.1016/S1470-2045(25)00602-3
  2. Asian Spine J. 2026 Feb 04.
       Study Design: Retrospective cohort study.
    Purpose: To identify whether the presence and features of epidural metastases are risk factors for metastatic spinal cord compression (MSCC).
    Overview of Literature: Several factors are associated with the development of MSCC in patients with spinal metastases. However, the relationship between epidural metastasis and the development of MSCC is not well understood.
    Methods: Among patients with spinal metastases at the spinal cord level treated at a single institution from 2017 to 2023, 191 cases (age: 66.4±12.9 years; sex: 120 male patients) were studied. We defined MSCC as a decrease of one or more grades in the American Spinal Injury Association (ASIA) impairment scale due to spinal metastases. Patients were diagnosed with epidural metastasis at the level of spinal metastasis. When the features of epidural metastases could be evaluated, the epidural spinal cord compression (ESCC) scale and circumferential angle of spinal cord compression (CASCC) were assessed. The risk factors for developing MSCC and high-risk epidural metastases were analyzed.
    Results: Of the patients with spinal metastases who developed MSCC during follow-up, 97.6% had epidural metastases before the onset of MSCC. Multivariate logistic regression analysis identified the presence of epidural metastasis as an independent risk factor for MSCC. In patients with evaluable epidural metastases, multivariate logistic regression analysis identified the ESCC scale and CASCC as high-risk factors. The cutoffs were determined to be 3 for the ESCC scale and 180° for CASCC.
    Conclusions: Epidural metastasis was identified as a risk factor for MSCC in patients with spinal metastases. Additionally, epidural metastases in those with an ESCC scale of 3 and a CASCC greater than 180° were categorized as high-risk tumors.
    Keywords:  Epidural metastases; Metastatic spinal cord compression; Risk factors; Spinal metastases
    DOI:  https://doi.org/10.31616/asj.2025.0489
  3. JAMA Netw Open. 2025 Dec 01. 8(12): e2549685
       Importance: Metastasis-directed stereotactic body radiotherapy (SBRT) may be a viable strategy to defer systemic therapy in patients with oligometastatic cancer due to comorbidities, patient preferences, or concerns about adverse effects. To date, the evidence supporting this approach has not been comprehensively assessed.
    Objective: To evaluate systemic therapy-free survival (STFS) for different types of oligometastatic cancer after SBRT alone and to quantify adverse events, quality of life, and oncological outcomes.
    Data Sources: A systematic search of PubMed and EMBASE was conducted on July 10, 2024, to identify potentially eligible studies published after 2009. Forward and backward citation tracking was performed to identify additional relevant studies.
    Study Selection: Studies eligible for inclusion in the systematic review were retrospective or prospective with at least 10 patients who received metastasis-directed SBRT and no up-front systemic therapy for oligometastatic cancer (≤5 metastases) irrespective of primary tumor histology. Required outcomes being reported were STFS, progression-free survival, or overall survival. The subgroup of studies reporting STFS at 1 or 2 years were included in a meta-analysis of these pooled outcomes.
    Data Extraction and Synthesis: Two reviewers independently extracted data using predefined forms and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A random-effects model was used for meta-analysis.
    Main Outcomes and Measures: The primary outcome of the meta-analysis was the pooled STFS rate at 1 or 2 years.
    Results: Of 29 unique studies (2074 unique patients) included in the systematic review, 13 (984 patients) contributed data to the meta-analysis. The pooled 1- or 2-year STFS rate was 69.7% (95% CI, 57.4%-80.9%) across cancer types. Renal cell cancer demonstrated the highest STFS rate (87.0%; 95% CI, 76.2%-95.2%), followed by prostate cancer (78.1%; 95% CI, 67.4%-87.3%), with lower rates in other cancer types. Among 20 studies reporting adverse events, rates of adverse effects of grade 3 or higher were absent in 15 of 19 studies (79%) and ranged from 2 of 103 (1.9%) to 3 of 34 patients (8.8%) among those that observed severe adverse events.
    Conclusions and Relevance: In this systematic review and meta-analysis, metastasis-directed SBRT alone was associated with meaningful STFS, particularly in patients with oligometastatic prostate or renal cell cancer, with low risks of treatment-related adverse events. These findings suggest that SBRT alone might be an acceptable option instead of immediate systemic therapy in selected patients with oligometastatic cancer.
    DOI:  https://doi.org/10.1001/jamanetworkopen.2025.49685
  4. Cancer Med. 2026 Feb;15(2): e71520
       OBJECTIVES: To evaluate the performance of the Tokuhashi, Tomita, SORG machine learning (SORG ML), and OPTImodel algorithms as survival predictors for vertebral metastases in clinical practice.
    MATERIALS AND METHODS: A retrospective study (2013-2023) analyzed 573 patients from Cabueñes University Hospital (Asturias, Spain). Thirty-two demographic, epidemiological, clinical, and analytical variables were considered, including diagnosis chronology and survival.
    RESULTS: Among the 573 patients studied, 272 (47.4%) presented visceral metastases at the time of diagnosis. A total of 362 patients (63.2%) had associated comorbidities. The most frequent primary histological diagnoses in these patients were lung 147 (25.7%), prostate 146 (25.5%), breast 118 (20.6%), kidney 30 (5.2%), and colorectal 29 (5.1%). The median survival of the cohort was 185 days. The accuracy rates for the Tokuhashi, SORG ML, OPTImodel, and Tomita algorithms were 0.5509, 0.4812, 0.3404, and 0.3858, respectively. The models with the highest accuracy rates in specific time segments were Tokuhashi (77.5% for < 6 months) and OPTImodel (90.8% for more than 1 year). The areas under the curve (AUC) for survival intervals were as follows: Tokuhashi at 42 days (73.19%), 90 days (79.3%), and 365 days (82.73%); Tomita at 42 days (69.27%), 90 days (76.82%), and 365 days (78.79%); SORG ML at 42 days (52.77%), 90 days (51.69%), and 365 days (51.38%).
    CONCLUSIONS: All models showed relatively low accuracy. The newer models (OPTImodel, SORG ML) did not outperform the traditional Tomita and Tokuhashi in predicting survival for vertebral metastases patients.
    DOI:  https://doi.org/10.1002/cam4.71520
  5. JNCI Cancer Spectr. 2026 Feb 04. pii: pkag010. [Epub ahead of print]
       BACKGROUND: Radiotherapy (RT) plays a crucial role in managing cancer-related symptoms. This study characterized symptom documentation, especially pain, preceding bone metastasis (BM) diagnosis and initiation of RT for BM, using natural language processing (NLP) approaches.
    METHODS: A de-identified cohort of patients who received RT for BM at a single tertiary-care institution (2013-2023) was created. Clinical data, notes, and metadata were computationally extracted. A previously validated NLP pipeline based on the clinical Text Analysis and Knowledge Extraction System was used to extract CTCAE-encoded symptoms from all notes in the 30 days preceding BM diagnosis and each course of RT for BM. Logistic regression analyses examined the association between clinical and demographic variables and pain documentation.
    RESULTS: 1,061 patients (median [IQR] age, 64 [54-72] years; 582 [54.9%] men) received 1,718 courses of RT for BM. The most common documented symptoms before BM diagnosis and first RT for BM, respectively, were BM-related pain (52.5% vs 91.6%, p < .001), nausea (20.8% vs 48.9%, p < .001), and constipation (12.8% vs 34.2%, p < .001). Prior to BM diagnosis, multiracial/other race (OR = 0.61 [95% CI 0.38-0.99], p = .045) was associated with decreased pain documentation compared to white race. Prior to RT for BM, women (OR = 1.48 [95% CI 1.02-2.15], p = .039) had increased pain documentation compared to men.
    CONCLUSIONS: Women and multiracial/other race patients experienced a relative increase in pain documentation from BM diagnosis to RT for BM. This may reflect differential decision-making for which patients are offered RT for BM sooner in the symptom trajectory. Interventions are needed to increase equitable distribution of RT.
    Keywords:  Natural language processing; bone metastases; metastatic cancer; pain; radiotherapy; symptoms
    DOI:  https://doi.org/10.1093/jncics/pkag010